Castration-resistant prostate cancer: novel therapeutics pre- or post- taxane administration.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Current Cancer Drug Targets

• Publication date

  2013-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/15680096113139990078PMID 23517595
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cabazitaxel: a novel drug for hormone-refractory prostate cancer.

  2013cited by this paper
• Abiraterone in metastatic prostate cancer without previous chemotherapy.

  2013cited by this paper
• ETS1 promotes chemoresistance and invasion of paclitaxel-resistant, hormone-refractory PC3 prostate cancer cells by up-regulating MDR1 and MMP9 expression.

  2012cited by this paper
• Antioxidant therapy alleviates oxidative stress by androgen deprivation and prevents conversion from androgen dependent to castration resistant prostate cancer.

  2012cited by this paper
• Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.

  2012cited by this paper
• Increased survival with enzalutamide in prostate cancer after chemotherapy.

  2012cited by this paper
• ARN-509: a novel antiandrogen for prostate cancer treatment.

  2012cited by this paper
• High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non–Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway

  2012cited by this paper
• Tumorigenic polyploid cells contain elevated ROS and ARE selectively targeted by antioxidant treatment

  2012cited by this paper
• Gender Influences the Class III and V β-Tubulin Ability to Predict Poor Outcome in Colorectal Cancer

  2012cited by this paper
• Clusterin mediates TGF-β-induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells.

  2012cited by this paper
• Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone.

  2012cited by this paper
• Pharmaco-economic aspects of Sipuleucel-T

  2012cited by this paper
• Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer

  2012cited by this paper
• Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target.

  2011cited by this paper
• Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer.

  2011cited by this paper
• Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.

  2011cited by this paper
• Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy.

  2011cited by this paper
• Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer.

  2011cited by this paper
• The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.

  2011cited by this paper
• Characterisation and manipulation of docetaxel resistant prostate cancer cell lines

  2011cited by this paper
• Clusterin Is a Critical Downstream Mediator of Stress-Induced YB-1 Transactivation in Prostate Cancer

  2011cited by this paper
• Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c

  2011cited by this paper
• Alternatively spliced androgen receptor variants.

  2011cited by this paper
• Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castration-resistant prostate cancer.

  2011cited by this paper
• Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer

  2011cited by this paper
• Akt, FoxO and regulation of apoptosis.

  2011cited by this paper
• Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.

  2011cited by this paper
• Clusterin induces matrix metalloproteinase‐9 expression via ERK1/2 and PI3K/Akt/NF‐κB pathways in monocytes/macrophages

  2011cited by this paper
• Pituitary tumor transforming gene induces epithelial to mesenchymal transition by regulation of Twist, Snail, Slug, and E-cadherin.

  2011cited by this paper
• TGF-β-stimulated aberrant expression of class III β-tubulin via the ERK signaling pathway in cultured retinal pigment epithelial cells.

  2011cited by this paper
• Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants

  2011cited by this paper
• New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway

  2011cited by this paper
• Direct Regulation of Androgen Receptor Activity by Potent CYP17 Inhibitors in Prostate Cancer Cells*

  2011cited by this paper
• Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.

  2011cited by this paper
• TGF-β/SMAD/GLI2 signaling axis in cancer progression and metastasis.

  2011cited by this paper
• Abiraterone and increased survival in metastatic prostate cancer.

  2011cited by this paper
• Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel

  2011cited by this paper
• Chemotherapy sensitivity recovery of prostate cancer cells by functional inhibition and knock down of multidrug resistance proteins

  2011cited by this paper
• Hsp27 Protects Adenocarcinoma Cells from UV-Induced Apoptosis by Akt and p21-Dependent Pathways of Survival

  2010cited by this paper
• Downmodulation of Bcl‐2 sensitizes metastatic LNCaP‐LN3 cells to undergo apoptosis via the intrinsic pathway

  2010cited by this paper
• Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer

  2010cited by this paper
• Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.

  2010cited by this paper
• Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression

  2010cited by this paper
• Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

  2010cited by this paper
• Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.

  2010cited by this paper
• Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.

  2010cited by this paper
• Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor.

  2010cited by this paper
• Transcriptome profiling of a TGF-β-induced epithelial-to-mesenchymal transition reveals extracellular clusterin as a target for therapeutic antibodies

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Glutaredoxin Regulates Apoptosis in Cardiomyocytes via NFκB Targets Bcl-2 and Bcl-xL: Implications for Cardiac Aging

  2010cited by this paper
• CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer

  2010cited by this paper
• Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance.

  2010cited by this paper
• Fibronectin confers survival against chemotherapeutic agents but not against radiotherapy in DU145 prostate cancer cells: Involvement of the insulin like growth factor‐1 receptor

  2010cited by this paper
• Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

  2010cited by this paper
• TWISTing an embryonic transcription factor into an oncoprotein

  2010cited by this paper
• Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

  2010cited by this paper
• Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

  2010cited by this paper
• Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.

  2010cited by this paper
• CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel‐induced cytotoxicity

  2010cited by this paper
• Induction of Clusterin by AKT—Role in Cytoprotection against Docetaxel in Prostate Tumor Cells

  2010cited by this paper
• Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling.

  2009cited by this paper
• Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer

  2009cited by this paper
• Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.

  2009cited by this paper
• Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition.

  2009cited by this paper
• Sphingosine kinase 1 inhibition sensitizes hormone‐resistant prostate cancer to docetaxel

  2009cited by this paper
• Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

  2009cited by this paper
• Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs

  2009cited by this paper
• Docetaxel–ST1481 sequence exerts a potent cytotoxic activity on hormone‐resistant prostate cancer cells by reducing drug resistance‐related gene expression

  2009cited by this paper
• Increased expression of class III β-tubulin in castration-resistant human prostate cancer

  2009cited by this paper
• A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.

  2009cited by this paper
• Regulation of HSP27 on NF-κB pathway activation may be involved in metastatic hepatocellular carcinoma cells apoptosis

  2009cited by this paper
• Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

  2009cited by this paper
• Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth.

  2009cited by this paper
• PTEN genomic deletion is associated with p‐Akt and AR signalling in poorer outcome, hormone refractory prostate cancer

  2009cited by this paper
• Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.

  2009cited by this paper
• Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

  2009cited by this paper
• Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.

  2009cited by this paper
• NF-kappaB regulates androgen receptor expression and prostate cancer growth.

  2009cited by this paper
• Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

  2008cited by this paper
• Class III β-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel

  2008cited by this paper
• Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.

  2008cited by this paper
• N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma

  2008cited by this paper
• Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.

  2008cited by this paper
• Androgen receptor‐dependent regulation of Bcl‐xL expression: Implication in prostate cancer progression

  2008cited by this paper
• Clusterin knockdown using the antisense oligonucleotide OGX‐011 re‐sensitizes docetaxel‐refractory prostate cancer PC‐3 cells to chemotherapy

  2008cited by this paper
• The PIM1 Kinase Is a Critical Component of a Survival Pathway Activated by Docetaxel and Promotes Survival of Docetaxel-treated Prostate Cancer Cells*

  2008cited by this paper
• Protein abundance of class III beta-tubulin but not Delta2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site.

  2008cited by this paper
• Twist promotes tumor cell growth through YB-1 expression.

  2008cited by this paper
• Bicalutamide failure in prostate cancer treatment: involvement of Multi Drug Resistance proteins.

  2008cited by this paper
• Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice.

  2008cited by this paper
• Transforming growth factor-beta and Wnt signals regulate chondrocyte differentiation through Twist1 in a stage-specific manner.

  2007cited by this paper
• Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer.

  2007cited by this paper
• Prognostic implications of the nuclear localization of Y‐box‐binding protein‐1 and CXCR4 expression in ovarian cancer: Their correlation with activated Akt, LRP/MVP and P‐glycoprotein expression

  2007cited by this paper
• Anti‐apoptotic role of TWIST and its association with Akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells

  2007cited by this paper
• Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

  2007cited by this paper
• Id-1 promotes TGF-beta1-induced cell motility through HSP27 activation and disassembly of adherens junction in prostate epithelial cells.

  2007cited by this paper
• Upregulation of Twist-1 by NF-κB Blocks Cytotoxicity Induced by Chemotherapeutic Drugs

  2007cited by this paper
• Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel.

  2007cited by this paper
• Extracellular heat shock protein 90: A role for a molecular chaperone in cell motility and cancer metastasis

  2007cited by this paper

• Genetic variations predicting progression with docetaxel and novel androgen‐receptor pathway inhibitors

  2023cites this paper
• A Phase II Trial of Abiraterone With Dutasteride for Second‐Generation Antiandrogen‐ and Chemotherapy‐Naïve Patients With Castration‐Resistant Prostate Cancer

  2022cites this paper
• High‐throughput screen identifies 5‐HT receptor as a modulator of AR and a therapeutic target for prostate cancer

  2020cites this paper
• Impact of antiandrogen withdrawal syndrome in castration‐resistant prostate cancer patients treated with abiraterone or enzalutamide

  2020cites this paper
• Prognostic and Predictive Factors for Anti-androgen Withdrawal in Castration-resistant Prostate Cancer

  2018cites this paper
• FOXO3a Expression Regulated by ERK Signaling is Inversely Correlated With Y‐Box Binding Protein‐1 Expression in Prostate Cancer

  2017cites this paper
• Clinical Outcomes of First‐line Abiraterone Acetate or Enzalutamide for Metastatic Castration‐resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone‐sensitive Prostate Cancer

  2017cites this paper
• Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.

  2017cites this paper
• Targeting fatty acid synthase with ASC‐J9 suppresses proliferation and invasion of prostate cancer cells

  2016cites this paper
• Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy

  2016cites this paper
• Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy

  2016cites this paper
• Lx2-32c, a novel semi-synthetic taxane, exerts antitumor activity against prostate cancer cells in vitro and in vivo

  2016cites this paper
• Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7.

  2016cites this paper
• Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone‐sensitive prostate cancer

  2016cites this paper
• Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer.

  2015cites this paper
• SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.

  2015cites this paper
• Prognostic Impact of Serum Testosterone and Body Mass Index Before Androgen-deprivation Therapy in Metastatic Prostate Cancer.

  2015cites this paper
• The oncological outcome and validation of Japan Cancer of the Prostate Risk Assessment score among men treated with primary androgen-deprivation therapy

  2015cites this paper
• Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer

  2014cites this paper
• The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer.

  2014cites this paper
• Targeting ribosomal S6 kinases/Y‐box binding protein‐1 signaling improves cellular sensitivity to taxane in prostate cancer

  2014cites this paper